8.62
price up icon4.74%   0.39
 
loading
Precedente Chiudi:
$8.23
Aprire:
$8.23
Volume 24 ore:
870.98K
Relative Volume:
0.77
Capitalizzazione di mercato:
$494.31M
Reddito:
$89.04M
Utile/perdita netta:
$-241.08M
Rapporto P/E:
-1.6388
EPS:
-5.26
Flusso di cassa netto:
$-194.72M
1 W Prestazione:
+0.94%
1M Prestazione:
-16.71%
6M Prestazione:
+9.67%
1 anno Prestazione:
-19.81%
Intervallo 1D:
Value
$8.14
$8.79
Intervallo di 1 settimana:
Value
$7.91
$8.99
Portata 52W:
Value
$5.035
$15.36

Regenxbio Inc Stock (RGNX) Company Profile

Name
Nome
Regenxbio Inc
Name
Telefono
240-552-8181
Name
Indirizzo
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Name
Dipendente
353
Name
Cinguettio
@REGENXBIO
Name
Prossima data di guadagno
2025-03-04
Name
Ultimi documenti SEC
Name
RGNX's Discussions on Twitter

Confronta RGNX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
RGNX
Regenxbio Inc
8.62 494.31M 89.04M -241.08M -194.72M -5.26
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Regenxbio Inc Stock (RGNX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-02-11 Downgrade Goldman Buy → Neutral
2025-02-07 Ripresa Raymond James Outperform
2024-11-15 Ripresa Morgan Stanley Overweight
2024-10-10 Ripresa Raymond James Outperform
2024-06-07 Iniziato Goldman Buy
2024-03-11 Iniziato H.C. Wainwright Buy
2024-03-08 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2024-03-06 Aggiornamento Leerink Partners Market Perform → Outperform
2024-02-21 Ripresa Raymond James Outperform
2023-11-01 Iniziato Stifel Buy
2023-06-02 Iniziato Robert W. Baird Outperform
2022-06-23 Iniziato Berenberg Buy
2021-12-15 Iniziato Wedbush Neutral
2021-10-19 Ripresa Morgan Stanley Overweight
2021-01-06 Aggiornamento Raymond James Outperform → Strong Buy
2020-12-16 Iniziato UBS Buy
2020-06-25 Ripresa BofA/Merrill Buy
2020-05-13 Iniziato RBC Capital Mkts Sector Perform
2019-08-20 Aggiornamento SVB Leerink Underperform → Mkt Perform
2019-06-18 Reiterato Chardan Capital Markets Buy
2019-06-14 Ripresa Raymond James Outperform
2019-06-05 Reiterato Chardan Capital Markets Buy
2019-02-25 Aggiornamento Evercore ISI In-line → Outperform
2019-02-05 Aggiornamento Raymond James Outperform → Strong Buy
2018-12-17 Reiterato Chardan Capital Markets Buy
2018-11-08 Reiterato BofA/Merrill Neutral
2018-08-08 Reiterato Chardan Capital Markets Buy
2018-07-23 Downgrade BofA/Merrill Buy → Neutral
2018-07-10 Reiterato Chardan Capital Markets Buy
2018-05-09 Reiterato Barclays Overweight
2018-04-09 Reiterato Chardan Capital Markets Buy
2018-03-12 Downgrade Evercore ISI Outperform → In-line
2018-02-13 Iniziato Mizuho Neutral
2017-11-09 Ripresa Morgan Stanley Overweight
Mostra tutto

Regenxbio Inc Borsa (RGNX) Ultime notizie

pulisher
Jun 16, 2025

Regenxbio (RGNX) Maintains Strong Outlook Amid Competitor Safety Concerns | RGNX Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 15, 2025

REGENXBIO announces royalty monetization agreement for up to $250M - MSN

Jun 15, 2025
pulisher
Jun 14, 2025

REGENXBIO (RGNX) Prepares for Potential $4M Warrant Cash Influx - GuruFocus

Jun 14, 2025
pulisher
Jun 13, 2025

Regenxbio (RGNX) Proposes Sale of Over 268,000 Shares | RGNX Stock News - GuruFocus

Jun 13, 2025
pulisher
Jun 09, 2025

Regenxbio (RGNX) Maintains Buy Rating with $52 Price Target | RGNX Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

A Glimpse Into The Expert Outlook On Regenxbio Through 8 Analysts - Benzinga

Jun 09, 2025
pulisher
Jun 09, 2025

Promising RGX-202 Trial Results Justify Buy Rating for RegenXBio Amid Market Skepticism - TipRanks

Jun 09, 2025
pulisher
Jun 07, 2025

REGENXBIO updates Phase 1/2 data for Duchenne candidate - MSN

Jun 07, 2025
pulisher
Jun 06, 2025

Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrome - Seeking Alpha

Jun 06, 2025
pulisher
Jun 06, 2025

H.C. WAINWRIGHT MAINTAINS BUY RATING ON REGENXBIO STOCK AFTER POSITIVE TRIAL DATA - Investing.com Nigeria

Jun 06, 2025
pulisher
Jun 06, 2025

Duchenne gene therapy interim trial outcomes "striking" - MarketScreener

Jun 06, 2025
pulisher
Jun 06, 2025

Otsuka tops Vera with kidney drug data; Regenxbio sinks on Duchenne update - BioPharma Dive

Jun 06, 2025
pulisher
Jun 06, 2025

RegeNXBio shares fall, despite positive new data on RGX-202 - The Pharma Letter

Jun 06, 2025
pulisher
Jun 05, 2025

REGENXBIO reports progress in Duchenne treatment trial By Investing.com - Investing.com South Africa

Jun 05, 2025
pulisher
Jun 05, 2025

Regenxbio’s Duchenne gene therapy data positive as shares falter - BioWorld MedTech

Jun 05, 2025
pulisher
Jun 05, 2025

New Regenxbio DMD Data Support Gene Therapy Accelerated Approval - insights.citeline.com

Jun 05, 2025
pulisher
Jun 05, 2025

Stifel reiterates Buy rating on Regenxbio stock after trial data By Investing.com - Investing.com Nigeria

Jun 05, 2025
pulisher
Jun 05, 2025

Stifel reiterates Buy rating on Regenxbio stock after trial data - Investing.com Australia

Jun 05, 2025
pulisher
Jun 05, 2025

REGENXBIO reports new positive functional data from phase I/II AFFINITY Duchenne® trial of RGX-202 - Pipelinereview

Jun 05, 2025
pulisher
Jun 05, 2025

Regenxbio’s Gene Therapy Helps Kids with Deadly Muscle Disease - Bloomberg

Jun 05, 2025
pulisher
Jun 05, 2025

Transcript : REGENXBIO Inc.Special Call - MarketScreener

Jun 05, 2025
pulisher
Jun 05, 2025

Regenxbio (RGNX) Reports Positive Data for RGX-202 Gene Therapy Trial - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Regenxbio (RGNX) Reports Promising Interim Results for Duchenne Therapy | RGNX Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

REGENXBIO reports progress in Duchenne treatment trial - Investing.com Australia

Jun 05, 2025
pulisher
Jun 05, 2025

REGENXBIO stock in focus after data for Duchenne drug (RGNX) - Seeking Alpha

Jun 05, 2025
pulisher
Jun 05, 2025

Regenxbio Reports New Positive Functional Data From Phase I/Ii Affinity Duchenne® Trial Of Rgx-202 - MarketScreener

Jun 05, 2025
pulisher
Jun 05, 2025

REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II A - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World

Jun 05, 2025
pulisher
Jun 05, 2025

REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202 | RGNX Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202 - PR Newswire

Jun 05, 2025
pulisher
Jun 03, 2025

RegenXBio Holds 2025 Annual Stockholders Meeting - TipRanks

Jun 03, 2025
pulisher
Jun 03, 2025

ProShare Advisors LLC Boosts Stake in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

Bank of America Corp DE Reduces Stock Holdings in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World

Jun 03, 2025
pulisher
Jun 02, 2025

REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202 - Eagle-Tribune

Jun 02, 2025
pulisher
Jun 02, 2025

REGENXBIO to Host Webcast Discussing Interim Functional Data fro - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202 | RGNX Stock News - GuruFocus

Jun 02, 2025
pulisher
May 31, 2025

Leerink Partnrs Weighs in on REGENXBIO FY2026 Earnings - Defense World

May 31, 2025
pulisher
May 30, 2025

Ameriprise Financial Inc. Has $2.20 Million Stake in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World

May 30, 2025
pulisher
May 28, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $775,000 Stock Position in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World

May 28, 2025
pulisher
May 26, 2025

D. E. Shaw & Co. Inc. Raises Position in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World

May 26, 2025
pulisher
May 26, 2025

REGENXBIO’s SWOT analysis: gene therapy firm’s stock poised for growth By Investing.com - Investing.com UK

May 26, 2025
pulisher
May 26, 2025

REGENXBIO’s SWOT analysis: gene therapy firm’s stock poised for growth - Investing.com Australia

May 26, 2025
pulisher
May 25, 2025

REGENXBIO Inc. (NASDAQ:RGNX) Shares Bought by Deutsche Bank AG - Defense World

May 25, 2025
pulisher
May 23, 2025

Finance Watch: Public Company Fundraising Sank Across The Board In Q1 - insights.citeline.com

May 23, 2025
pulisher
May 22, 2025

REGENXBIO’s $250 Million Royalty Bond Agreement with HealthCare Royalty - Global Legal Chronicle

May 22, 2025
pulisher
May 21, 2025

Coave Therapeutics Establishes New Scientific Advisory Board to Accelerate Innovation in Genetic Medicines for Eye and CNS Diseases - GlobeNewswire Inc.

May 21, 2025

Regenxbio Inc Azioni (RGNX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Regenxbio Inc Azioni (RGNX) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Mills Kenneth T.
Director
May 12 '25
Sale
7.91
20,602
163,046
475,103
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Capitalizzazione:     |  Volume (24 ore):